AnaptysBio Analyst Ratings
Wedbush Reiterates Outperform on AnaptysBio, Maintains $34 Price Target
Wedbush Reaffirms Their Buy Rating on AnaptysBio (ANAB)
Buy Rating Affirmed for AnaptysBio Amidst Promising Pipeline and Strategic Financial Positioning
Buy Rating Affirmed for AnaptysBio on Positive Development Outlook and Market Potential
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), AnaptysBio (ANAB) and LivaNova (LIVN)
AnaptysBio Analyst Ratings
AnaptysBio Analyst Ratings
AnaptysBio Analyst Ratings
AnaptysBio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), AnaptysBio (ANAB) and ITeos Therapeutics (ITOS)
J.P. Morgan Reaffirms Their Hold Rating on AnaptysBio (ANAB)
Strong Buy Rating for AnaptysBio Based on Promising Pipeline and Financial Health
AnaptysBio Analyst Ratings
AnaptysBio Analyst Ratings
AnaptysBio Analyst Ratings
Wedbush Reiterates Neutral on AnaptysBio, Maintains $20 Price Target
AnaptysBio Analyst Ratings
Truist Financial Reaffirms Their Hold Rating on AnaptysBio (ANAB)
AnaptysBio Analyst Ratings
No Data